• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing Erasca (ERAS) Valuation After FDA Trial Hold And New ERAS-0015 Patent

    Simply Wall St·01/08/2026 23:27:53
    Listen to the news

    FDA clinical hold and new patent shift Erasca’s risk profile

    The key trigger for Erasca (ERAS) was the FDA’s partial clinical hold on its Phase 1 BOREALIS-1 trial for ERAS-4001, paired with fresh patent protection for its pan-RAS molecular glue ERAS-0015.

    See our latest analysis for Erasca.

    After a sharp pre-market drop on the clinical hold news, Erasca’s recent catalyst mix, including the ERAS-0015 patent and competitor data in pan-KRAS, has coincided with a 90-day share price return of 141.08% and a 1-year total shareholder return of 111.27%. This suggests momentum has been building into a higher risk, higher potential setup at a current share price of $5.81.

    If Erasca’s story has caught your eye, this is also a good moment to scan other healthcare names and see how they stack up through healthcare stocks.

    With Erasca now at US$5.81, recent gains and a price target that sits slightly below today’s level raise a key question for investors: is the market already baking in future growth, or is there still a genuine entry point?

    Price-to-Book of 4.7x: Is it justified?

    With Erasca closing at US$5.81 and trading on a P/B of 4.7x, the stock currently sits at a premium to both peers and the broader US biotechs group.

    P/B compares the company’s market value to its net assets, which is often used for early stage biotech names that have limited or no revenue and are still loss making. For Erasca, where reported revenue is US$0 and the company posted a net loss of US$127.69m, investors are effectively paying for the pipeline and intellectual property rather than current earnings.

    The 4.7x P/B is higher than the US biotechs industry average of 2.7x and also above the peer average of 4x. This indicates a clear valuation premium, with the market assigning Erasca a richer multiple than many comparable companies. This suggests expectations for its RAS/MAPK portfolio are more optimistic than the group as a whole.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 4.7x (OVERVALUED)

    However, you are also facing trial uncertainty from the FDA clinical hold on ERAS-4001 and ongoing losses of US$127.69m, which rely on future funding.

    Find out about the key risks to this Erasca narrative.

    Build Your Own Erasca Narrative

    If you see the data differently or prefer to stress test your own view, you can build a complete Erasca thesis yourself in just a few minutes, starting with Do it your way.

    A great starting point for your Erasca research is our analysis highlighting 3 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    If Erasca is on your radar, this is the moment to widen your watchlist and stress test your thinking against other high conviction ideas across the market.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.